Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.830
+0.040 (2.23%)
At close: Dec 20, 2024, 4:00 PM
1.880
+0.050 (2.72%)
After-hours: Dec 20, 2024, 7:03 PM EST

Akebia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
399234106395405752
Upgrade
Market Cap Growth
29.30%120.08%-73.16%-2.30%-46.16%16.23%
Upgrade
Enterprise Value
468301121363241640
Upgrade
Last Close Price
1.831.240.582.262.806.32
Upgrade
PS Ratio
2.191.200.361.871.372.24
Upgrade
PB Ratio
-5.51-7.6420.305.341.631.90
Upgrade
P/TBV Ratio
----8.3615.50
Upgrade
EV/Sales Ratio
2.761.550.411.710.821.91
Upgrade
EV/EBITDA Ratio
106.22-39.44---
Upgrade
Debt / Equity Ratio
-2.05-3.4130.072.560.510.27
Upgrade
Debt / EBITDA Ratio
10.97-18.82---
Upgrade
Asset Turnover
0.770.650.660.360.420.38
Upgrade
Inventory Turnover
1.382.130.771.670.720.91
Upgrade
Quick Ratio
1.010.821.010.791.590.90
Upgrade
Current Ratio
1.521.181.431.041.981.49
Upgrade
Return on Equity (ROE)
---237.83%-175.37%-119.82%-54.27%
Upgrade
Return on Assets (ROA)
-9.37%-9.30%-4.89%-24.27%-15.41%-19.74%
Upgrade
Return on Capital (ROIC)
-32.60%-23.56%-10.17%-44.71%-24.88%-30.24%
Upgrade
Earnings Yield
-11.52%-22.23%-88.77%-71.32%-95.09%-37.20%
Upgrade
FCF Yield
-9.65%-10.01%-69.03%-63.99%-27.35%-35.13%
Upgrade
Buyback Yield / Dilution
-9.55%-2.56%-10.14%-19.85%-16.95%-104.00%
Upgrade
Total Shareholder Return
-9.55%-2.56%-10.14%-19.85%-16.95%-104.00%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.